Síndrome serotoninérgico como reacción adversa infrecuente ante la sinergia entre Linezolid y Fentanilo: presentación de caso

  • Jose Leonel Zambrano-Urbano Universidad Libre Seccional Cali. Colombia
  • José Mauricio Ocampo-Chaparro Universidad del Valle. Cali, Colombia.
  • Eduardo Lerma-Flórez Universidad del Valle. Cali, Colombia.
  • María Eugenia Casanova Universidad Libre Seccional Cali. Colombia

Resumen

El síndrome serotoninérgico es una condición potencialmente mortal causada por medicamentos que afectan el metabolismo de la
serotonina o que actúan como agonistas directos del receptor de esta o una combinación de ambos. El síndrome da lugar a una variedad
de manifestaciones mentales, autonómicas y neuromusculares, que pueden variar desde leves hasta potencialmente mortales. Se reporta
el caso clínico de un paciente el cual desarrolló este síndrome por la coadministración y sinergismo de linezolid y fentanilo, con una
gran variedad de características clínicas, desde las más sutiles, como cifras tensionales altas de difícil manejo mientras se encontraba
bajo el efecto de sedoanalgesia, hasta las manifestaciones más floridas del síndrome posterior a la suspensión de esta. La asociación de
estos medicamentos representa una etiología poco informada que puede favorecer la aparición del síndrome, mientras que el uso de
benzodiazepinas puede enmascarar el cuadro dificultando su diagnóstico. MÉD.UIS.2020;33(3): 59-66

Descargas

La descarga de datos todavía no está disponible.

Referencias

1. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. Int J Tryptophan Res [Internet]. 2019 Sep 9;12:1178646919873925. Disponible en: 10.1177/1178646919873925.

2. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) [Internet]. 2000 Jul;79(4):201-9. Disponible en: 10.1097/00005792-200007000-00001.

3. Jurek L, Nourredine M, Megarbane B, d’Amato T, Dorey JM, Rolland B. The serotonin syndrome: An updated literature review. Rev Med Interne [Internet]. 2019 Feb;40(2):98-104. Disponible en: 10.1016/j.revmed.2018.08.010.

4. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med [Internet]. 2005 Mar 17;352(11): 1112-20. Disponible en: 10.1056/ NEJMra041867.

5. Bartlett D. Drug-Induced Serotonin Syndrome. Crit Care Nurse [Internet]. 2017 Feb;37(1):49-54. Disponible en: 10.4037/ ccn2017169.
6. Karkow DC, Kauer JF, Ernst EJ. Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy. J Clin Psychopharmacol [Internet]. 2017 Oct;37(5):518–23. Disponible en:
0.1097/JCP.0000000000000751.

7. Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Physician. 2018;64(10):720-27

8. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-13

9. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications. J Clin Psychiatry. 2014;75(2):169-177.

10. Nguyen CT, Xie L, Alley S, McCarron RM, Baser O, Wang Z. Epidemiology and economic burden of serotonin syndrome with
concomitant use of serotonergic agents: A retrospective study utilizing two large US claims databases. Prim Care Companion CNS Disorder. 2017;19(6).

11. Watson WA, Litovitz TL, Klein-Schwartz W, Rodgers GC, Reid N, Youniss J, et al. 2004 Annual Report of the American Association of Poison
ontrol Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005;23(5):589-666.

12. Watson WA, Litovitz TL, Rodgers GC Jr, Klein-Schawartz, Youniss J, Rose SR. 2002 Annual Report of the American Association of
Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2003;21(5):353-421.

13. Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th annual report. Clin Toxicol. 2017;55(10):1072-1252.

14. Isbister G, Buckley N. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28(5):205-14

15. Werneke U, Jamshidi F, Taylor D, Ott M. Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases. BMC Neurol. 2016;16:97.

16. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49(448):871-874.

17. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2019;20(9):2288.

18. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotoninergic disorders. Am
Acad of Pain Med. 2003; 4(1): 63-74.

19. 19. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533‐540.

20. Dosi R, Ambaliya A, Joshi H, Patell R. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep. 2014;2014(1):bcr2014204154.

21. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13(4):763-783.

22. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642.

23. Boyer EW, Traub SJ, Grayzel J. Serotonin Syndrome. In: UpToDate, Waltham, MA, 2010.

24. Lawrence K, Adra M, Gillman P. Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. Clin Infect Dis. 2006;42(11), 1578–1583.

25. Mandell L, Bennett E, Dolin R: Principles and Practice of Infectious Diseases, 5th edition. Churchill Livingstone, Inc. 2000. pp. 392–393.

26. Samartzis L, Savvari P, Kontogiannis S, Dimopoulos S. Linezolid Is Associated with Serotonin Syndrome in a Patient Receiving Amitriptyline, and Fentanyl: A Case Report and Review of the Literature. Case Rep Psychiatry. 2013;2013(3): 617251.

27. Frank, Christopher. Recognition and treatment of serotonin syndrome. Frank C. Recognition and treatment of serotonin syndrome. Can Fam Physician. 2008;54(7):988-992.

28. Bronstein A, Spyker D, Cantilena L, Rumack B, Dart R. Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila). 2012; 50(10): 911 – 1164.

29. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47(6):1824–1831.

30. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43(2):180–187. 31.
homas CR, Rosenberg M, Blythe V, et al. Serotonin syndrome and linezolid. J Am Acad Child Adolesc Psychiatry. 2004;43(7):790.

32. Taylor JJ, Estes LL, Wilson JW. Linezolid and serotonergic drug interactions. Clin Infect Dis. 2006;43(2):180–187.

33. Strouse TB, Kerrihard TN, Forscher CA, et al. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. J Clin Psychopharmacol. 2006;26(6):681–683.

34. Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry. 2009;11(6):353-356.

35. Ramsay R, Dunford C, Gillman P. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007;152(6): 946 - 951.

36. Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ. 2003;168(11):1439-1442.

37. Young P, Finn BC, Pellegrini D, Soloaga ED, Bruetman JE. Tormenta simpatica paroxistica siguiendo a injuria axonal difusa. Medicina (B.
ires). 2006;66(5): 439-42.
Publicado
2020-12-22
Sección
Presentación de caso